Publications by authors named "Sofia Zompi"

Background: Bloodstream infections (BSIs) are a serious threat for patients undergoing allogenic hematopoietic stem cell transplants (a-HSCT). MDR colonization is highly prevalent among a-HSCT patients, due to drug-induced intestinal dysbiosis. Primary outcome of the study was to assess the epidemiology and risk factors for BSIs in the 1st year after a-HSCT.

View Article and Find Full Text PDF

Background: Despite the adoption of pediatric-like chemotherapy protocols, the introduction of new immunotherapies and a better understanding of the oncogenic landscape, the outcome for adult patients with acute lymphoblastic leukemia (ALL) remain substantially dismal. The aim of the present study was to evaluate the outcome in terms of survival in a cohort of adult patients with ALL who received allogeneic hematopoietic stem cell transplantation (alloSCT) between 2013 and 2023.

Methods: This was a single-center observational retrospective study including all consecutive adult patients with ALL who received an alloSCT between April 2013 and April 2023 at the Stem Cell Transplant Center AOU Città della Salute e della Scienza of Torino.

View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic has severely affected individuals with hematological malignancies due to their weakened immune systems, resulting in higher mortality rates and severe outcomes.
  • Data from the EPICOVIDEHA registry, which compiles COVID-19 cases from these patients worldwide, was collected from 2020 to 2022, including 8,767 cases from 152 centers across 41 countries.
  • Findings show a significant drop in critical infections and overall mortality rates, but hospitalization (especially in ICU) remains a serious risk factor; vaccination is linked to better survival outcomes, highlighting the need for ongoing monitoring and support for these patients.
View Article and Find Full Text PDF
Article Synopsis
  • * In a retrospective analysis of 226 patients from 2008 to 2021, the study found a cumulative incidence of 29.9% for acute GVHD and 29.8% for chronic GVHD, along with 1, 2, and 3-year non-relapse mortality rates of 18.2%, 19.6%, and 20.2%, respectively.
View Article and Find Full Text PDF
Article Synopsis
  • * 326 patients were analyzed, showing that COVID-19 severity ranged from mild to critical, with 21% of patients experiencing mild cases and an overall mortality rate of 21%.
  • * Key risk factors for higher mortality included being over 50 years old, having multiple comorbidities, active hematologic disease, and experiencing COVID-19 within a year of transplantation.
View Article and Find Full Text PDF

Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021.

View Article and Find Full Text PDF